On March 6, 2019 Ipsen (Euronext: IPN; ADR: IPSEY) reported the EU launch of a new pre-filled syringe for Somatuline Autogel (lanreotide) for patients with neuroendocrine tumors (NETs), acromegaly or symptoms associated with carcinoid syndrome, and released findings from the human factor studies that underpinned its development as a poster presentation (Abstract #H14) at ENETS 2019.1,2 As of April 2019, patients in Ireland will be the first to benefit from the new ready-to-use, pre-filled syringe (Press release, Ipsen, MAR 6, 2019, View Source [SID1234534071]). Ipsen has confirmed they are committed to making this new pre-filled syringe available to patients and healthcare professionals throughout Europe, the U.S., Canada, Australia and New Zealand during 2019 following necessary regulatory approvals.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The new pre-filled syringe for Somatuline Autogel was the result of several studies, involving patients, their caregivers, nurses and other healthcare professionals, to inform and test enhancements to the existing pre-filled syringe.1 Notable new features are modified ergonomics and handling, a needle shield removal system, an injection process with plunger support and heightened ease of use.1 The automatic, built-in safety system, which helps to prevent needle stick injury by locking in place following the administration, has not been changed.
"Today’s announcement around the EU launch of a new pre-filled syringe for Somatuline Autogel is not only an important new option for patients living with acromegaly and NETs but represents a significant milestone in our commitment to patient-centric innovation," said Bartek Bednarz, Senior Vice President, Global Oncology Franchise at Ipsen. "We are also proud to be sharing as a poster presentation at ENETS 2019 the results of several studies, where we tested, evolved and validated changes for every stage of the Somatuline Autogel injection experience", added Sotirios Stergiopoulos, Chief Medical Officer at Ipsen.
"NETs and acromegaly can be associated with a number of uncomfortable and unpleasant symptoms, so any innovation that eases the physical challenges of treatment for the patient and their healthcare team is a step forward," said Daphne T Adelman, Clinical Nurse Specialist from Northwestern University in Chicago, U.S. and one of the authors of the study.